Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020
January 29, 2021Los Angeles Biotechnology Network NewsNewsComments Off on Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented interim results from the Phase II SUMMIT Trial of Neratinib for EGFR exon 18-mutated, metastatic NSCLC at WCLC 2020.